EP3924367A2 - Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée - Google Patents

Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée

Info

Publication number
EP3924367A2
EP3924367A2 EP20908461.5A EP20908461A EP3924367A2 EP 3924367 A2 EP3924367 A2 EP 3924367A2 EP 20908461 A EP20908461 A EP 20908461A EP 3924367 A2 EP3924367 A2 EP 3924367A2
Authority
EP
European Patent Office
Prior art keywords
vegf
sequence
minutes
ice
followed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20908461.5A
Other languages
German (de)
English (en)
Other versions
EP3924367A4 (fr
Inventor
Anoop Kumar Thekkuveettil
Sheeja Liza EASO
Geethu SHAJI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sree Chitra Tirunal Institute For Medical Sciences And Technology
Original Assignee
Sree Chitra Tirunal Institute For Medical Sciences And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sree Chitra Tirunal Institute For Medical Sciences And Technology filed Critical Sree Chitra Tirunal Institute For Medical Sciences And Technology
Publication of EP3924367A2 publication Critical patent/EP3924367A2/fr
Publication of EP3924367A4 publication Critical patent/EP3924367A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a recombinant growth factor vascular endothelial growth factor with fully functioning active peptide, expressible in expression system(s), and a process of preparation thereof.
  • Growth factors are endogenous signaling polypeptides between cells which acts by binding to specific receptors on the surface of their target cells. These help in stimulating cell proliferation, growth, differentiation and healing.
  • Growth factors have a good role in recruiting many attractive agents which enhance the rate of healing around the wound area. They will help in regulating the cellular responses required for wound healing process such as migration, proliferation and differentiation.
  • VEGF Vascular endothelial growth factor
  • FGF Fibroblast Growth Factor
  • PDGF Plater Derived Growth Factor
  • epidermal growth factor VEGF
  • VEGF is a 45 kDa heterodimeric heparin-binding signal polypeptide expressed in endothelial cells, comes under the sub family of growth factors, is also known as vascular permeability factor.
  • VEGF is primarily involved in vasculogenesis (de novo formation of embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature).
  • VEGF vascular endothelial growth factor
  • VEGF and its receptors primarily expressed in endothelial cells, it is expressed well in non-endothelial cells like tumor cells, macrophages, platelets, keratinocytes, and renal mesangial cells. So, the up regulation of VEGF and VEGF receptors can initiate tumor.
  • VEGF family comprises five (5) groups members namely VEGF-A (placenta growth factor), VEGF-B, VEGF-C and VEGF-D.
  • VEGF proteins encoded in viruses VEGF-E
  • VEGF-F snake venom
  • VEGF has a prominent role in several facets of the wound repair process by initiating angiogenesis, it is a strong inducer of vascular permeability in the skin. As it increases angiogenesis, it results in the formation of more blood vessels around the wound region and thereby improving more supply of oxygen and blood around the wound region.
  • wound healing is a chronic process, which involves the recruitment of several signals which helps in the proliferation, differentiation of the wound area. So, protein molecules which enhance the rate of wound healing will help in faster healing of wounds.
  • the growth factors can perform a number of events which ultimately results in the wound healing. In our invention we are developing such a growth factor which can do some positive actions in the wound area
  • the inventors have achieved the development of mature VEGF using prokaryotic expression system, with a minimal production cost and capable of delivering to a suitable scaffold vehicle to the wound site which heal the chronic wounds by recruiting more blood vessels to the wound site, thus, initiates a better healing.
  • Recombinant human VEGF have been found critical in treating surgical wounds as well as in the therapy of diabetic foot ulcers.
  • US 11541848 discloses purifying of a peptide, polypeptide or protein from a biological sample said method comprising subjecting the biological sample to affinity chromatography to purify human origin VEGF-B.
  • US 08915795 isolates VEGF that can stimulate at least one endothelial cell biological activity.
  • WO 1999037671 A1 isolated nucleic acid molecules that encode novel molecules related to the VEGF family to stimulate angiogenesis, by administration of a therapeutically effective amount of a VEGF-R antagonist.
  • US 10792480 discloses VEGF-C protein and gene, mutants thereof. And uses thereof by purifying and isolating a polypeptide which is capable of binding to the Flt4 receptor tyrosine kinase and the extracellular domain of Flt4 receptor tyrosine kinase and stimulates Flt4 autophosphorylation.
  • US 6180107 B1 discloses VEGF II, a heterodimer protein which, stimulates mitogenesis of mammalian vascular endothelial cells, and proven to be useful for the promotion of vascular development and repair.
  • US 20030166547 A1 disclosed a method of inducing angiogenesis in a tissue in need of angiogenesis.
  • US 20030215921 A1 discloses a biologically active VEGF 2 polypeptide, a nucleic acid vector construct, which can be administrated in chronic limb ischemic patients.
  • US 20030215921 A1 worked on VEGF-2.
  • US5194596 A discloses the production of VEGF.
  • US 5194596 A isolated VEGF selected from the group consisting of bovine vascular endothelial cell growth factor of 120 amino acids, and human VEGF of 121 amino acids.
  • OBJECTS OF THE PRESENT INVENTION It is therefore an object of this invention to develop a growth factor which helps in bringing more blood vessels to the wound area. Another objective of the study is to create active peptide which enhances wound healing in a very short time period.
  • Yet another objective of this invention is to combine the developed growth factor with another growth factors which helps in wound healing
  • Still another objective of the invention is to deliver the growth factors to a suitable scaffold which suites the skin.
  • the present invention discloses a recombinant growth factor vascular endothelial growth factor with fully functioning active peptide, expressed in prokaryotes, with a Glutathione S - Transferase (GST) tag, purified to 80-90 %, a fully functioning active peptide, so it doesn’t need any further post translational modification for its action.
  • GST Glutathione S - Transferase
  • the prokaryotic expression system makes the recombinant growth factor VEGF-D cost effective.
  • the fully functioning active peptide is synthesized by specially selecting the active sequence which targets angiogenesis.
  • using the low-cost procedure of protein isolation protocol and bulk protein purification protocol by eluting out all the bacterial impurities using affinity columns which can be reused.
  • primers for reverse transcriptase-polymerase chain reaction for cloning the c-DNA obtained from VEGF, comprising a reverse primer and a forward primer under SEQUENCE ID NO.: 1 and 2 respectively, has been disclosed.
  • an active peptide, a 352 base pair (bp) fragment from the whole VEGF-D gene) which specifically regulates the cellular functions down regulates wound healing is prepared.
  • the forward primer is 28 bp with the GC percentage is 44.8, and a melting temperature of 70.9° C, said sequence is deliberated under SEQUENCE ID NO.: 2, and the reverse primer is 32 bp with the GC percentage is 43.8, and a melting temperature of 72.5° C, said sequence is detailed under SEQUENCE ID NO.: 1.
  • the peptide is having a purity of 80-90%, which does not make allergic reactions in humans, a functionally active peptide of vascular endothelial growth factor (VEGF) of SEQUENCE ID NO.: 3 for enhancing angiogenesis especially in wounds by binding to the receptors in the wound cells without undergoing any post-translational modifications.
  • VEGF vascular endothelial growth factor
  • the present invention discloses primers for reverse transcriptase-polymerase chain reaction (RT-PCR) for cloning the c-DNA obtained from VEGF, comprising a forward primer and a reverse primer.
  • RT-PCR reverse transcriptase-polymerase chain reaction
  • the present invention discloses a process of preparation of VEGF for enhancing angiogenesis especially in wounds by binding to the receptors in the wound cells without undergoing any post-translational modifications, said process comprising the steps of isolating the RNA of VEGF (SEQUENCE ID NO.: 3) performed through washing with water, grounding using motor and pestle in liquid nitrogen, adding RNA lysis solution and homogenizing for short pulse using tissue homogenizer, treating with DNase I for 15 min and purifying by phenol chloroform and precipitating with ammonium acetate and isopropanol; RT-PCR of VEGF using primers of SEQUENCE ID NO.: 1 and 2, and collecting the purified c DNA performed by mixing 7 pi of isolated RNA with 1 m ⁇ of VEGF, and incubating for 5 minutes at 70° C, followed by cooling down using ice, adding with 4 m ⁇ of 5X RT-PCR buffer, 10 mM dNTP, 0.5 m ⁇ of RNAse inhibitor of 30
  • a pharmaceutical composition comprising essentially of SEQUENCE ID NO.: 3 along with other additives, carriers, excipients and other filler materials, is disclosed.
  • Figure 1 a. 352 bp-long VEGF-D gene fragment used for expressing mature peptide; and b. Over expression of VEGF on IPTG induction.
  • one or more elements in a system or device proceeded by “comprises... a” does not, without more constraints, preclude the existence of other elements or additional elements in the system, apparatus or device.
  • the terms “a” and“an” mean one or more, and the term“or” means and/or.
  • the meaning of “a.” “an,” and“the” includes plural reference unless the context clearly dictates otherwise.
  • the meaning of“in” includes “in” and“on” unless the context clearly dictates otherwise.
  • the principle aim of the invention is to develop a functionally active peptide of VEGF, specifically of VEGF-D, for that the peptide of VEGF-D is designated, then it is coned into a resistant vector supplemented with a particular antibiotic resistance.
  • VEGF-D VEGF has been used, and it may be understood that wherever the reference of VEGF with respect to this present invention has been mentioned, said VEGF is VEGF-D, sequence of which is appended as SEQUENCE ID NO.: 4.
  • the vector may be any vector selected from plasmids, phasmids, viral vectors, cosmids, and artificial chromosomes or the likes.
  • the vector is a DNA/ RNA molecule used as a vehicle to artificially carry foreign genetic material into another cell, where it can be replicated and / or expressed, therefore, the vector must be free-floating, and able to carry a desired information.
  • Antibiotic resistance is the ability of a microorganism to withstand the effects of an antibiotic. It is a specific type of drug resistance, which can be a useful way of implanting artificial genes into the microorganism. Antibiotic resistance is a consequence of evolution via natural selection. To ensure the retention of plasmid DNA in bacterial populations, an antibiotic resistance gene is included in the plasmid.
  • Any antibiotic resistant gene will have a specific segment ensuring the resistance against a particular antibiotic, including but not limited to ampicillin, streptomycin, amoxicillin, penicillin or the likes.
  • an ampicillin resistant gene may be selected for the recombinant vector.
  • said tagging may be chemical or using bioluminescence.
  • a glutathione S transferase (GST) tag has been used specifically to purify our protein of interest from the bacterial protein, said system is expressed in a prokaryotic host system.
  • the VEGF thus synthesized will specifically target the wound healing pathway. As the mature peptide has been synthesized, it can directly bind to the receptors in the wound cells without undergoing any further post translational modifications. Since the gene is cloned and expressed in a prokaryotic system, it makes the invention cost effective.
  • the GST tag used to purify our protein of interest from the bacterial protein does its task to 80-90%.
  • the VEGF mature peptide with 352 bp, deliberated under SEQUENCE ID NO.: 3 can be isolated from a donor tissue where angiogenesis is high, said tissue may be any skeletal or involuntary or cardiac muscles.
  • RNA of human heart tissue was isolated and VEGF cDNA was prepared.
  • the cDNA, thus obtained was then subject to polymerase chain reaction (PCR) using forward and reverse primers.
  • RNA was isolated from discarded heart tissue bits. These tissues are discarded, and although derived from the biological world, however, doesn’t constitute a part of the biological world, and may be considered like hairs and nails, the collection of which doesn’t take any pleasant or unpleasant effect on the donor.
  • the tissue may be collected from anywhere, however, the collection point is Sree Chitra Tirunal Institute for Medical Sciences.
  • RNA lysis solution was added and homogenized for short pulse using tissue homogenizer. Isolated RNA was treated with DNase I for 15 min and purified by phenol chloroform and precipitated with ammonium acetate and isopropanol. The RNA pellet was dissolved in 15ul sterile water.
  • RNA is isolated from discarded heart tissue bits. The tissue is washed with water, ground using motor and pestle in liquid nitrogen. To be finely powdered tissue, RNA lysis solution is added and homogenized for short pulse using tissue homogenizer. Isolated RNA is treated with DNase I for 15 min and purified by phenol chloroform and precipitated with ammonium acetate and isopropanol. The RNA pellet was dissolved in 15 pi sterile water.
  • Example 2
  • Primer designing is the primordial part of this step, namely forward and reverse primers, which are designed based on the RNA obtained from the atrial appendage, and corresponding cDNA.
  • the length of the reverse primer is 32 bp with the GC percentage is 43.8, and a melting temperature of 72.5° C, said sequence is detailed under SEQUENCE ID NO.: 1.
  • the length of the forward primer is 28 bp with the GC percentage is 44.8, and a melting temperature of 70.9° C, said sequence is deliberated under SEQUENCE ID NO.: 2.
  • PCR Polymerase Chain Reaction
  • RNA thus isolated is mixed with 1 m ⁇ of VEGF, and incubated for 5 minutes at 70° C, followed by cooling down using ice. This was then added with 4 m ⁇ of 5X RT-PCR buffer, 10 mM dNTP, 0.5 m ⁇ of RNAse inhibitor of 30 U/ m ⁇ , and finally mixed with 5 m ⁇ of nuclease free deionized water followed by incubation at 37° C for 5 minutes. Following this incubation, 0.5 m ⁇ of 200 U / m ⁇ M-MuFV reverse transcriptase is added. This mixture is again incubated at 42° C for 60 minutes for the reaction to occur, said reaction is then stopped by heating at 70° C for 10 minutes.
  • Table showing the cycles of said PCR is
  • the reaction mixture of PCR comprises 10.5 m ⁇ of nuclease free deionized water, 1 m ⁇ each of VEGF forward and reverse primers, 1 m ⁇ of 10 mM dNTP, 2 m ⁇ of 25 mM magnesium chloride (MgCk), 2.5 m ⁇ of 10 X PCR buffer, 2 m ⁇ of 1 U / m ⁇ Taq polymerase, and 5 m ⁇ of cDNA obtained, thus making a resultant volume of 25 m ⁇ .
  • Example 4 Example 4:
  • cDNA Complementary DNA of VEGF was made from mRNA isolated from discarded human heart tissue.
  • VEGF having a size of 352 bp is amplified from the cDNA. and then the amplified VEGF was eluted from the gel using QIAquick PCR purification kit. The purified product was further confirmed by agarose gel electrophoresis with 360 base pair length.
  • ligation For the ligation, 1 m ⁇ of pTZ57R/T is added to 10 m ⁇ of VEGF; and in the mixture, 1.5 m ⁇ 10 X cohesive end ligase buffer is added. This is then followed by addition of 1 m ⁇ of PEG 4000 and BSA (bovine serum albumin) each, followed by final addition of 0.5 m ⁇ of T4 DNA ligase.
  • PEG 4000 and BSA bovine serum albumin
  • the TA cloned VEGF gene is expressed in XL1 Blue by electroporation and it is screened using blue white screening method. Later plasmid is isolated and VEGF forward clone is confirmed with 364 base pair and 2884 base pair using the restriction enzyme Bam HI, the forward primer for VEGF PCR constitutes Bam HI site.
  • VEGF/pTZ5 clones are ligated to the vector pGEX4Tl having a size of 4929 base pair, by incubating a reaction mixture at overnight, said reaction mixture constitutes 8 m ⁇ each of pTZ/ VEGF, 10X Bam H I Buffer, 10 U / m ⁇ Bam HI restriction enzyme, along with 63.5 m ⁇ of nuclease free deionized water.
  • the amplified product is screened and selected by transforming XL1 blue cells.
  • XL1 Blue strain is added into 5 ml of LB media aka luria broth at 37°C rotating at 200 rpm overnight. 2 ml of this initial day’s culture is inoculated to 100 ml of LB broth, and incubated at 37°C rotating at 200 rpm till the time the OD (Optical Density) reaches 0.4. Then the culture was transferred to 50 ml sterile polypropene tubes duly sealed thereafter with paraffin. This is followed by inoculation on ice, and then keeping for rotation at 4,500 rpm for 10 minutes at 4°C.
  • the supernatant is decanted, and the pellets are resuspended in 5 ml ice cold CaCL of 200 mM. This is then kept in ice for 20 minutes, resuspended the pellets in 15 ml of 80 mM CaCL, kept on ice for 20 minutes, and stored in fridge for further use.
  • T ransf ormation Incubation is done with 100 pi of competent cells and 1 pi of plasmid in a sterile tube for 30 minutes on ice, then the heat shock is applied at 42° C for 90 seconds with immediate storing in ice, followed by adding 500 m ⁇ of LB broth media, keeping at 37° C for 45 minutes at 350 rpm.
  • 1 ml culture of VEGF is inoculated into 100 mL of LB ampR media and incubated at 37°C at 200 rpm. When the OD reaches 0.6, 0.1 mM IPTG is added, then incubated for 3 hours at 200 rpm at 37°C. The cultures are then transferred to centrifuge tubes wherein the centrifugation is performed at 500 g for 15 minutes at 4°C. The pellets are then kept aside and resuspended using 1 ml of IX PBS (Phosphate Buffer Saline), followed by addition of lysozyme at a concentration of 1 mg/ ml, vortexed and kept in ice for 30 minutes.
  • IX PBS Phosphate Buffer Saline
  • the isolated crude protein which includes the bacterial as well as the protein of interest having 41 KDa was separated by Glutathione S transferase (GST) column chromatography .
  • An affinity chromatography procedure is done with a glutathione Sepharose 4B column.
  • This column matrix helps in binding GST Fusion proteins, which upon on contact with glutathione reduced elution buffer decrease its affinity towards Sepharose 4B and bind off from the stationary phase.
  • the purified proteins are qualitatively analyzed using SDS PAGE. The purity of the protein is ⁇ 80 - 90%.
  • the column is pre-equilibrated using the column of IX PBS in 10 bed volume, and the crude protein sample is clarified with 0.22 mm filter syringe and passed through the column.
  • the column is cleaned with 2 ml of IX PBS between each sample application.
  • the column is then eluted with 6 ml of reduced glutathione buffer, and elution fractions are collected and stored.
  • the column is then re equilibrated with 20 ml of IX PBS.
  • composition A pharmaceutical composition comprising essentially of SEQUENCE ID NO.: 3 along with other additives, carriers, excipients and other filler materials.
  • the pharmaceutical composition may be in the form of tablet or capsule or sublingual administration tablets or the likes, or liquid or suspension or injectable or patch or cream or ointment or gel like topical formulation for topical administration or the likes.
  • the preferred route is oral or injectable.
  • a pharmaceutical composition for the preferred oral or sublingual route of administration can be obtained by combining SEQUENCE NO.: 3 with conventional pharmaceutical additives and excipients used in the art for sublingual preparations.
  • Appropriate formulation methods are well known to the person skilled in the art; see, for instance, Pharmaceutical Dosage Forms: Tablets. Volume 1, 2nd Edition, Lieberman H A et ah; Eds.; Marcel Dekker, New York and Basel 1989, p. 354-356, and literature cited therein.
  • Suitable additives comprise additional carrier agents, preservatives, lubricants, gliding agents, disintegrants, flavorings, and dyestuffs as state of the art knowledge is concerned.
  • a disintegrating agent may be incorporated in the composition of the invention, wherein such an agent will accelerate the dispersion of the carrier particles.
  • disintegrating agents according to the invention include cross-linked polyvinylpyrrolidone, carboxymethyl starch, natural starch, microcrystalline cellulose, cellulose gum and mixtures of in 1% to 10% of the composition.
  • the modus operandi of disintegrating agent and the bio/ mucoadhesion promoting agent overlap somewhat, and it may be preferred that both functions are served by the same substance. However, it is important to note that these two categories of excipients are not equivalent, and there are efficiently functioning disintegrants which do not possess bio/mucoadhesive properties, and vice versa.
  • solid, non-porous spheres allows to have a precise knowledge of the mass- surface relationship of particles and therefore, by virtue of a selection of the size of the spheres, that is to say of the radius or of a distribution of radii, to have a precise control of the rate of release of the active ingredient or active ingredients administered, thus, by avoiding overdosages or the need to compensate for underdosages, makes it possible to reduce the total administration of the biologically active substance SEQUENCE ID NO.: 3 to the minimum quantity required in order to obtain the desired therapeutic effect and thereby decrease the risk of producing undesirable secondary effects in the patient.
  • Microspheres may be prepared of decreasing the volume of solid material which has to be injected into a living organism, having the advantage of not using a low- melting excipient, those particles could agglutinate and cause handling problems upon injection along with the advantage of not introducing unnecessary solid excipient, more or less degradable, into the organism.
  • a number of substances may be combined with adjuvants not directly active on the receiving organism, said combination may comprise various pharmaceutically acceptable additive means for increasing the stability or chemical integrity of the biologically active substances, it being understood that they are not vector type excipients.
  • it may become useful to decrease the melting point or to inhibit a decomposition reaction during the microsphere manufacturing process through melting-freezing or the likes.
  • the microspheres may be classified and separated more finely and more reliably as a function of their size than irregularly shaped particles.
  • the formulation according to the present invention may also be provided in the form of microsphere powder in vials-ampoules ready for making into a suspension, or in the form of a suspension ready prepared in injectable ampoules ready for administering in human or veterinary medicine differing only in dosage.
  • the suspension medium may be sterile water, a sterile saline solution, an oil containing the buffers, surfactants or preservatives conventionally employed in injectable suspensions by pharmacists, or any other substance or combination, which does not threaten the physical and chemical integrity of the substances in suspension and which is suitable for the organism which will receive it.
  • the use will be preferred, in the case of ready-for-use suspensions, of liquid vectors in which the said active ingredients are practically insoluble.
  • active substances partially soluble in the lukewarm liquid vector but insoluble at cold temperature, it is preferable, from the pharmacological point of view, to avoid the formation of precipitates i.e. to avoid any undesired caking effect by preparing formulations in the form of separate microsphere powder and liquid vector which will be mixed only at the time of injection.
  • the duration of desired effect may be very long like for the case of lactation in adult female animals
  • diameters of some hundreds of microns may be used. If it is desired to limit the diameter of needles for injection syringes for the comfort of the patient, it is good to limit the diameter of the microspheres to 300 microns and more preferably to 100 microns. In contrast, for very short durations of desired effect, such as circadian, the diameter of the microsphere may be reduced to 1 micron.
  • microspheres whose diameter is between 0.1 to 100 microns.
  • An essential condition for achieving the dosage form according to the present invention is to have batches of calibrated microspheres, that is to say homogeneous in diameter. Microspheres may also be separated according to their diameter during the manufacture using cyclonic separators, by sieving using air suction or by sieving in a liquid medium. If more than 70% of the microspheres have diameters of between 70% and 130% of a specified diameter, the condition may be referred sufficient. Mixing of batches with different suitable diameters may be done following the ideal dissolution curve as determined for the present invention.
  • Means like mechanical abrasion may be used so is suspension of the product in the melted state in the form of microdrops, with stirring, in a liquid vector with which the said product is non-miscible, followed by solidification of the said product.
  • Other method of obtaining porous microspheres like spraying, freezing and freeze-drying in a cold gas substances dissolved in a suitable solvent, may be employed.
  • the particles which are not in compliance with the specifications may be recycled.
  • An additive may also be used in order to eliminate a phase transition, from a solid phase to another solid phase, which is likely to weaken the structure of the sphere.
  • the process is also suited to mixtures of active substances in solid solution one inside the other.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne et revendique un peptide fonctionnellement actif de VEGF de SEQ ID NO : 3 par des amorces pour la RT-PCR pour cloner l'ADNc obtenu à partir du VEGF, comprenant une amorce sens de 28 p.b. sous SEQ ID NO : 2 et l'amorce antisens sous SEQ ID NO : 1 de 32 p.b. De plus, la présente invention concerne un procédé de préparation de VEGF comprenant les étapes consistant à isoler l'ARN du VEGF (SEQ ID NO : 3); effectuer la RT-PCR du VEGF à l'aide d'amorces de SEQ ID NO : 1 et 2, et à collecter l'ADNc purifié; ligaturer des clones tels qu'obtenus avec le vecteur pTZ57R/T; préparer des cellules compétentes; transformer des cellules clonées après sélection par l'intermédiaire d'une résistance aux antibiotiques dans un vecteur; isoler la protéine obtenue; et purifier de ladite protéine VEGF obtenue.
EP20908461.5A 2019-04-04 2020-04-02 Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée Withdrawn EP3924367A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941013671 2019-04-04
PCT/IN2020/050321 WO2020202214A2 (fr) 2019-04-04 2020-04-02 Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée

Publications (2)

Publication Number Publication Date
EP3924367A2 true EP3924367A2 (fr) 2021-12-22
EP3924367A4 EP3924367A4 (fr) 2022-10-12

Family

ID=72667624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20908461.5A Withdrawn EP3924367A4 (fr) 2019-04-04 2020-04-02 Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée

Country Status (2)

Country Link
EP (1) EP3924367A4 (fr)
WO (1) WO2020202214A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283268A3 (fr) * 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)

Also Published As

Publication number Publication date
WO2020202214A2 (fr) 2020-10-08
WO2020202214A4 (fr) 2021-03-11
WO2020202214A3 (fr) 2020-12-03
EP3924367A4 (fr) 2022-10-12

Similar Documents

Publication Publication Date Title
TWI866897B (zh) Ｆｇｆ２１變體、融合蛋白及其應用
JP2007535306A (ja) 線維芽細胞成長因子２１の突然変異タンパク質
JP2021529550A (ja) 可溶化アピラーゼ、方法及び使用
AU2017340387A1 (en) Targeted effector proteins and uses thereof
JP2001503265A (ja) 新規なｆｌｔ３受容体アゴニスト
CN102584976B (zh) 一种人血清淀粉样蛋白a1及其制备方法和应用
EP3924367A2 (fr) Facteur de croissance endothélial vasculaire (vegf) pour une meilleure cicatrisation de plaie par angiogenèse améliorée
CN113501862B (zh) 一种多肽及其在制备免疫调节药物中的应用
CN111714637B (zh) Vav1在制备治疗中枢神经系统炎症药物中的应用
Christ Frontiers in gene therapy for erectile dysfunction
CN102260352B (zh) 靶向性白细胞介素融合蛋白及其制备方法与应用
NL2030391B1 (en) Recombinant protein capable of resisting multiple sclerosis and preparation method and application thereof
EP3219798B1 (fr) Adn plasmidique codant pour hnp-1 ou hnp-2 ou hnp-3, producteur bactérien, produit analgésique (et variantes)
CN100535005C (zh) 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法
CN102370985A (zh) 钠尿肽受体a的激动剂在疼痛治疗中的用途
CN115605502A (zh) 用于预防或治疗纤维化疾病的重组融合蛋白
CN120324379B (zh) 一种具有抗炎作用的工程化细胞外囊泡及其制备方法
CN114369170B (zh) 基于靶向多效生长因子的神经胶质母细胞瘤治疗性融合蛋白、疫苗及其制备方法与用途
JP2002527112A (ja) ブタソマトトロピンのデリバリーシステム
US20220177533A1 (en) Recombinant TGF a for wound healing purposes, and the process thereof
WO2025241119A1 (fr) Protéine de fusion et utilisation associée
RU2753191C2 (ru) Новый рекомбинантный аналог гормона роста пролонгированного действия
CN100372572C (zh) 携带人胸腺素β4基因的重组质粒
CN106518995B (zh) 印鼠客蚤多肽及其基因和应用
CN100556455C (zh) 一种用于预防和治疗i型糖尿病的药物复合物及其应用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210804

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220909

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101ALI20220905BHEP

Ipc: A61K 39/00 20060101ALI20220905BHEP

Ipc: C07K 14/515 20060101AFI20220905BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230412